Regeneron BLA for Rilonacept Extended Three Months By FDA
This article was originally published in The Pink Sheet Daily
Executive Summary
Company has submitted additional data on chemistry, manufacturing and controls for the IL-1 Trap for rare inflammatory conditions.
You may also be interested in...
Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal
One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.
Sanofi Strengthens Monoclonal Antibody Access With $560 Million Regeneron Deal
One of the first candidates targeted for development will be an interleukin-6 receptor, a potential competitor to TNF inhibitors, for RA.
Regeneron Files BLA For IL-1 Trap Rilonacept To Treat Rare Inflammatory Conditions
Firm plans to pursue additional indications including gout, anemia and other inflammatory diseases for rilonacept.